Beta-blockers and the kidney.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects; D002302:Cardiac Output / Q000187:drug effects; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006439:Hemodynamics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects / Q000502:physiology*; D007674:Kidney Diseases / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D005082:Physical Exertion; D011412:Propanolamines / Q000009:adverse effects; D011433:Propranolol / Q000009:adverse effects; D012079:Renal Circulation / Q000187:drug effects*; D012083:Renin / Q000097:blood; D013566:Sympathomimetics; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D011412:Propanolamines; D013566:Sympathomimetics; D009248:Nadolol; D011433:Propranolol; D012083:Renin